BIOMAT Database Logo BIOMAT Database Logo

Plasma visfatin concentration as a surrogate marker for visceral fat accumulation in obese children. 2008

Shunsuke Araki, and Kazushige Dobashi, and Kazuyasu Kubo, and Rinko Kawagoe, and Yukiyo Yamamoto, and Yasusada Kawada, and Kohtaro Asayama, and Akira Shirahata
Department of Pediatrics, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.

OBJECTIVE This study was designed to elucidate whether the plasma visfatin level reflects visceral or subcutaneous fat accumulation and metabolic derangement in obese children. METHODS Fifty-six obese Japanese children, including 37 boys and 19 girls were enrolled in the study. The age of the subjects ranged from 5 to 15 (10.2 +/- 0.3; mean +/- s.e.m.) years. The age-matched control group for measuring visfatin consisted of 20 non-obese children. Visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) areas were measured by computed tomography. The plasma concentrations for visfatin and leptin were assayed by enzyme-linked immunosorbent assay kits. RESULTS The plasma visfatin level was higher in the obese (14.7 +/- 0.9 ng/ml) than in the control children (8.6 +/- 0.6 ng/ml). In a univariate analysis, the visfatin correlated significantly with age, height, body weight, waist circumference, VAT and SAT area, triglyceride (TG), insulin, and the homeostasis model assessment for insulin resistance (HOMA-R). After being adjusted for age and sex, only the VAT area retained significant partial correlation with visfatin, and in contrast the body weight, BMI-s.d., and SAT area with leptin. The plasma visfatin concentration was not correlated with leptin. The plasma visfatin levels in the control, non-metabolic syndrome (MS) (n = 49), and MS groups (n = 7) were significantly different from each other. CONCLUSIONS These results suggest that plasma visfatin level is a specific marker for visceral fat accumulation in obese children. As a good surrogate marker, plasma visfatin level can predict the VAT area in obese children.

UI MeSH Term Description Entries
D007564 Japan A country in eastern Asia, island chain between the North Pacific Ocean and the Sea of Japan, east of the Korean Peninsula. The capital is Tokyo. Bonin Islands
D008297 Male Males
D009765 Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
D001823 Body Composition The relative amounts of various components in the body, such as percentage of body fat. Body Compositions,Composition, Body,Compositions, Body
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D016022 Case-Control Studies Comparisons that start with the identification of persons with the disease or outcome of interest and a control (comparison, referent) group without the disease or outcome of interest. The relationship of an attribute is examined by comparing both groups with regard to the frequency or levels of outcome over time. Case-Base Studies,Case-Comparison Studies,Case-Referent Studies,Matched Case-Control Studies,Nested Case-Control Studies,Case Control Studies,Case-Compeer Studies,Case-Referrent Studies,Case Base Studies,Case Comparison Studies,Case Control Study,Case Referent Studies,Case Referrent Studies,Case-Comparison Study,Case-Control Studies, Matched,Case-Control Studies, Nested,Case-Control Study,Case-Control Study, Matched,Case-Control Study, Nested,Case-Referent Study,Case-Referrent Study,Matched Case Control Studies,Matched Case-Control Study,Nested Case Control Studies,Nested Case-Control Study,Studies, Case Control,Studies, Case-Base,Studies, Case-Comparison,Studies, Case-Compeer,Studies, Case-Control,Studies, Case-Referent,Studies, Case-Referrent,Studies, Matched Case-Control,Studies, Nested Case-Control,Study, Case Control,Study, Case-Comparison,Study, Case-Control,Study, Case-Referent,Study, Case-Referrent,Study, Matched Case-Control,Study, Nested Case-Control

Related Publications

Shunsuke Araki, and Kazushige Dobashi, and Kazuyasu Kubo, and Rinko Kawagoe, and Yukiyo Yamamoto, and Yasusada Kawada, and Kohtaro Asayama, and Akira Shirahata
Plasma concentration of visfatin is a new surrogate marker of systemic inflammation in type 2 diabetic patients.
August 2010, Diabetes research and clinical practice,
Shunsuke Araki, and Kazushige Dobashi, and Kazuyasu Kubo, and Rinko Kawagoe, and Yukiyo Yamamoto, and Yasusada Kawada, and Kohtaro Asayama, and Akira Shirahata
Central obesity as a clinical marker of adiposopathy; increased visceral adiposity as a surrogate marker for global fat dysfunction.
October 2014, Current opinion in endocrinology, diabetes, and obesity,
Shunsuke Araki, and Kazushige Dobashi, and Kazuyasu Kubo, and Rinko Kawagoe, and Yukiyo Yamamoto, and Yasusada Kawada, and Kohtaro Asayama, and Akira Shirahata
Plasma fat concentration increases in visceral fat obese men during high-intensity endurance exercise.
December 2007, Obesity research & clinical practice,
Shunsuke Araki, and Kazushige Dobashi, and Kazuyasu Kubo, and Rinko Kawagoe, and Yukiyo Yamamoto, and Yasusada Kawada, and Kohtaro Asayama, and Akira Shirahata
Association between plasma adiponectin concentration and visceral fat accumulation in hemodialysis patients.
January 2006, Nephron. Clinical practice,
Shunsuke Araki, and Kazushige Dobashi, and Kazuyasu Kubo, and Rinko Kawagoe, and Yukiyo Yamamoto, and Yasusada Kawada, and Kohtaro Asayama, and Akira Shirahata
The free testosterone to dehydroepiandrosterone sulphate molar ratio as a marker of visceral fat accumulation in premenopausal obese women.
October 1994, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity,
Shunsuke Araki, and Kazushige Dobashi, and Kazuyasu Kubo, and Rinko Kawagoe, and Yukiyo Yamamoto, and Yasusada Kawada, and Kohtaro Asayama, and Akira Shirahata
Plasma amino acid profile is associated with visceral fat accumulation in obese Japanese subjects.
February 2012, Clinical obesity,
Shunsuke Araki, and Kazushige Dobashi, and Kazuyasu Kubo, and Rinko Kawagoe, and Yukiyo Yamamoto, and Yasusada Kawada, and Kohtaro Asayama, and Akira Shirahata
Relationship between visceral fat accumulation and hypertension in obese men.
April 2003, Clinical and experimental hypertension (New York, N.Y. : 1993),
Shunsuke Araki, and Kazushige Dobashi, and Kazuyasu Kubo, and Rinko Kawagoe, and Yukiyo Yamamoto, and Yasusada Kawada, and Kohtaro Asayama, and Akira Shirahata
Increased plasma visfatin concentration is a marker of an atherogenic metabolic profile.
April 2013, Nutrition, metabolism, and cardiovascular diseases : NMCD,
Shunsuke Araki, and Kazushige Dobashi, and Kazuyasu Kubo, and Rinko Kawagoe, and Yukiyo Yamamoto, and Yasusada Kawada, and Kohtaro Asayama, and Akira Shirahata
Visceral fat accumulation as an important risk factor for obstructive sleep apnoea syndrome in obese subjects.
January 1997, Journal of internal medicine,
Shunsuke Araki, and Kazushige Dobashi, and Kazuyasu Kubo, and Rinko Kawagoe, and Yukiyo Yamamoto, and Yasusada Kawada, and Kohtaro Asayama, and Akira Shirahata
[Ultrasound measurement of visceral fat in obese children].
January 2004, Casopis lekaru ceskych,
Copied contents to your clipboard!